Reuters quoted three people familiar with the matter as reporting that Pfizer is exploring the sale of its hospital pharmaceutical business unit.

According to reports, Pfizer has hired Goldman Sachs to explore the initial interests of potential buyers, including private equity firms and other pharmaceutical companies.

People familiar with the matter told Reuters that the deal was not a foregone conclusion, and Pfizer may choose to keep the division.

Pfizer and Goldman Sachs declined to comment on Reuters.